The Reality and Recommendations for The Reimbursement Policy of Rare Diseases in the National Health Insurance Program
碩士 === 國立交通大學 === 科技法律研究所 === 105 === Whether drugs are recognized as a rare disease medication, and whether health insurances reimburses the drugs, often depend on the mechanisms of scientific and medical expert review meetings. The policymaking for rare diseases is often based on insufficient evi...
Main Authors: | Sung,Chun-Yi, 宋純儀 |
---|---|
Other Authors: | 陳鋕雄 |
Format: | Others |
Language: | zh-TW |
Published: |
2017
|
Online Access: | http://ndltd.ncl.edu.tw/handle/dtyx89 |
Similar Items
-
A Study on Reimbursement Policy of the National Health Insurance in Taiwan
by: 陳奕安 -
Strategic responses of hospitals in Taiwan to the new laber health insurance reimbursement rates
by: LI,CHUN-FU, et al.
Published: (1991) -
A Policy Study of National Health Insurance Program: Description, Evaluation and Recommendation
by: Yu, Hui-chun, et al.
Published: (1994) -
A current medical reimbursement practices and prospects for national health insurance
by: Kinney, Wallace D.
Published: (1977) -
The Study of the Responses of the Clinics to the Change of National Health Insurance Reimbursement System
by: Ying-Chia Huang, et al.
Published: (2005)